NV-ZTE-USA
ZTE USA, the fourth largest smartphone manufacturer in the U.S. and second largest in the no-contract market*, today announced the newly established ZTE Innovation Venture Fund at the 2015 Consumer Electronics Show (CES). The new fund is designed to bring unique and innovative mobile applications and content to the North American market. Select mobile application developers and startups will have their ideas come to fruition when distributed across ZTE’s global ecosystem that consists of a growing range of “smart” mobile devices, from smartphones to smart media streaming projectors.
“We’re excited to provide a path for young, growing and passionate startups to change the future of the wireless industry in unthought-of ways,” said Lixin Cheng, chairman and CEO of ZTE USA. “We see the potential within developers that can change the wireless market for the better if given the right support and financial resources.”
ZTE is providing more than equity or financing, but also strategic partnership opportunities to jointly innovate with their teams. ZTE also provides startups with a global audience through the tens of millions of smartphones shipped worldwide every year.
The first to join the ZTE Innovation Venture Fund is Azumio, the creator of the top weight-training and fitness application in the world, Fitness Buddy. Azumio is pioneering ways in which biofeedback can be used within mobile health applications for happier, healthier living.
“It’s exciting to be a part of the ZTE organization that is currently shaking things up during a critical transitional time for the wireless industry,” said Jeff Yee, vice president of technology planning and partnerships at ZTE USA. “We already have teams lined up that we believe in and who we think show promise in shifting the marketplace.”
Strategic investments and support provided by the ZTE Innovation Venture Fund will be led and managed by Jeff Yee, who created the first developer ecosystem for mobile commerce applications while at AT&T. Along with Jeff Yee, executive committee members, Lixin Cheng, chairman and CEO of ZTE USA and George Zhengzhi Hou, VP, ZTE Mobile Devices & Mobile Internet, will help direct investments for the ZTE Innovation Venture Fund.
Research and development has powered ZTE’s growth since 1985. Today, ZTE has 19 R&D centers and 10 joint innovation centers worldwide. ZTE will continue its commitment to research and innovation with increased R&D investments globally and North America to develop high-quality patents and product designs.
About ZTE USA
ZTE USA (www.zteusa.com ) is a subsidiary of ZTE Corporation, a leading global provider of mobile handsets, telecommunications equipment and network solutions. Operating since 1998, ZTE USA is dedicated to making cost-efficient, quality communication technology accessible to all. The company provides a magnitude of devices to every major US-based carrier, generates over $17.4 billion dollars’ worth of business for US-based companies and devotes more than 10 percent of its revenue to R&D. ZTE USA is headquartered in Richardson, Texas and operates 17 sales offices, customer service centers, R&D and distribution facilities across the US. ZTE is ranked as the country’s fourth-largest supplier of mobile devices overall, and second-largest supplier of prepaid devices, by independent analysts. ZTE is the Official Smartphone of the Golden State Warriors, Houston Rockets and New York Knicks.
Visit ZTE USA on YouTube https://www.youtube.com/user/ZTEUSAInc , LinkedIn https://www.linkedin.com/company/zteusa , Facebook https://www.facebook.com/ZTEUSA , and Twitter https://twitter.com/ZTE_USA .
*Strategy Analytics, North America Handset Vendor Market Share, Q3 2014
Contact:
ZTE USA
Andrew Elliott, 972-671-8885
andrew.elliott@zteusa.com
or
Grayling
for ZTE USA
Ashley Colette, 323-648-5420
Ashley.colette@grayling.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
LambdaTest Integrates with Assembla to Streamline Bug Tracking for Development Teams3.6.2025 17:00:00 CEST | Press release
This Integration enables teams with seamless bug tracking capabilities directly from the testing environment, enhancing collaboration and accelerating software delivery cycles. LambdaTest, a unified agentic AI and cloud engineering platform, has announced its partnership with Assembla, a robust cloud-based platform for version control and project management. This collaboration enables software development teams to streamline their bug tracking processes and improve overall productivity. LambdaTest offers developers an exhaustive list of cloud-based testing solutions, including cross-browser compatibility testing, Web and App automation testing, and Real Device testing. Assembla users can now easily integrate with the LambdaTest platform to seamlessly mark bugs with detailed screenshots and assign them to team members. "This integration between LambdaTest and Assembla allows development teams to optimize their testing and bug tracking processes," said Mayank Bhola, Co-Founder and Head o
The Future of AI in the AEC Industry Unveiled at BST Global’s 2025 AI Summit3.6.2025 16:41:00 CEST | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, hosted its second annual AI Summit, May 6–8, 2025, in Palm Beach, FL. The premier event brought together 12 thought leaders from some of the world’s most influential firms, including Arcadis, Arup, AtkinsRéalis, Gensler, GHD, Jacobs, Mott MacDonald, NVIDIA, Parsons, Stantec, and WSP to share insights on how AI is reshaping the future of the AEC industry. Attendees as well as the broader AEC community praised the 2025 AI Summit for its timely content and line-up of industry trailblazers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603538561/en/ BST Global Chief Executive Officer Javier A. Baldor officially kicks off the AI Summit’s first full day of sessions by presenting his perspective on the driving forces impacting the AEC industry and the world at large. He shares three key ways AI and big data will transform nearly
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 20253.6.2025 16:30:00 CEST | Press release
Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET)Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced that data from numerous programs in its hematology/oncology portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15, 2025, in Milan. "We're looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the no
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD3.6.2025 16:12:00 CEST | Press release
- Approval Based on Positive Results from the Phase 3 HD21 Trial for StageIIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe - Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS’ Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union Takeda(TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma i
Automotive Industry Shifts Gears As Talent and Technology Take Center Stage3.6.2025 16:00:00 CEST | Press release
Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 10th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 130 leaders across automotive and tire manufacturers, original equipment manufacturers, engineering procurement companies and systems integrators across 15 countries, revealing a sector rapidly embracing change to stay competitive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603797393/en/ Rockwell Automation report shows manufacturers are leaning into AI, upskilling and innovation to overcome workforce and operational challenges. Workforce pressures have emerged as the most urgent challenge for automot
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum